Sufenta

Sufentanil

Method of action: Anesthetic

Treatment option: Anesthesia, Vaginal Delivery, General Anesthesia, Delivery, Surgery

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sufenta

Property	Description
Active ingredient	Sufentanil
Form	Solution for injection, Sublingual tablets
Pharmacological class	Opioid Analgesic, General Anesthetic
General purpose	Profound pain relief, Inducing anesthesia
Origin	Synthetic Opioid (Phenylpiperidine derivative)

What is Sufentanil and What Type of Drug is it?

Sufenta is the trade name for the active substance Sufentanil, a powerful synthetic opioid analgesic primarily used in controlled clinical environments, and it is clinically recognized for its exceptional efficacy in pain management. The drug is classified as a narcotic analgesic and a general anesthetic. Its chemical identity defines it as a phenylpiperidine derivative and an analogue of fentanyl, establishing its origin as purely laboratory-synthesized.

The defining characteristic of Sufentanil is its profound potency, which is substantially greater than that of fentanyl. This strength stems from its mechanism as a full mu-opioid receptor agonist, strongly activating the central nervous system receptors responsible for controlling pain perception. This classification means it is reserved for the most extreme pain management scenarios, such as those encountered during major surgery, where its high efficacy is crucial. Its primary role is to manage pain that is severe and acute, particularly in procedural and surgical settings.

Composition, Forms, and General Therapeutic Purpose

The medicinal preparation contains Sufentanil, typically compounded as the highly stable and soluble citrate salt. In its most common form, the drug is manufactured as a sterile aqueous solution designed for parenteral routes of administration, including intravenous (IV), epidural, and intrathecal injection. A solid dosage form, the sublingual tablet, is also utilized in certified, medically supervised settings.

The general therapeutic purpose of the medication is two-fold: to provide immediate and profound analgesia (pain relief) and to induce and maintain anesthesia (unconsciousness) during high-stress operations. For instance, it is often utilized as part of the anesthetic regimen for complex cardiac surgery where hemodynamic stability is paramount. Its administration via injection allows for rapid onset of action and precise control over the patient's level of pain blockade and sedation, which is critical for maintaining stability during complex surgical procedures.

What side effects are possible with Sufenta?

Possible Side Effects and Safety Information

The official safety profile of Sufentanil (Sufenta) is strictly documented by government health authorities like the FDA and EMA, detailing expected adverse events and critical safety constraints associated with its use.

Adverse Reaction Scope

Category	Regulatory Documentation
Key Adverse Reactions	Nausea, Vomiting, Headache, Dizziness, Sedation, Hypotension, Bradycardia (slow heart rate), Muscular Rigidity (muscle stiffness), and Apnea (temporary cessation of breathing).
Frequency Classification	Adverse reactions are classified by frequency, with many being reported as Common or Very Common, such as nausea, vomiting, and hypotension, depending on the specific regulatory label and formulation.
System-Organ Classes	Effects are listed across several system-organ classes, including Respiratory Disorders (e.g., respiratory depression, apnea), Cardiac Disorders (e.g., bradycardia, cardiac arrest), Vascular Disorders (e.g., hypotension), and Nervous System Disorders (e.g., sedation, convulsions, rigidity).
Serious Adverse Reactions	The use of Sufentanil is associated with risks including Life-Threatening Respiratory Depression, Severe Circulatory Depression, Serotonin Syndrome (when used with certain other medications), Adrenal Insufficiency, and Neonatal Opioid Withdrawal Syndrome if used during pregnancy.

Regulatory Safety Constraints

The official documents define specific restrictions and special population considerations:

Population-Specific Safety: Older adults and those with hepatic or renal impairment may exhibit altered pharmacokinetics or increased sensitivity, requiring closer monitoring. Patients with chronic pulmonary disease carry a greater risk of life-threatening respiratory depression.
Dose-Related Patterns: Muscular rigidity is related to the dose and the speed of intravenous administration. Respiratory depression can occur at any time, but close observation is critical during initiation and following additional doses.
Restrictions and Limitations: Sufentanil is contraindicated in patients with hypersensitivity to the drug, or those with significant respiratory depression or acute bronchial asthma in unmonitored settings. Concomitant use with CNS depressants is noted to increase the risk of profound sedation and respiratory depression.

Connection to the Overall Safety Profile

This official safety information structures the drug's risk understanding around its high potential for serious, life-threatening adverse reactions, which is consistent with its classification as a potent opioid anesthetic. This profile necessitates the strict inclusion of safety limitations and special population-specific considerations in regulatory documentation, defining the controlled environment required for its administration.

Overdose and Emergency Response

Sufentanil overdose is defined in regulatory documents by critical, life-threatening clinical manifestations. The primary concern is life-threatening respiratory depression, which can quickly lead to apnea, coma, and death if not immediately addressed. Other documented signs of overdose include profound sedation progressing to stupor, miosis (pinpoint pupils), hypotension, and, in some cases, skeletal muscle rigidity or flaccidity.

The official guidance mandates that individuals seek immediate medical attention for any documented sign of overdose. Due to the high potency of Sufentanil, accidental exposure, particularly in children, is considered a medical emergency and can be fatal. Population-specific considerations note that elderly, debilitated patients and those with hepatic or renal impairment face an increased risk of severe, prolonged respiratory depression.

Management priorities are centered on the reestablishment of a patent airway and the institution of assisted or controlled ventilation. An opioid antagonist, such as naloxone, is the specific antidote indicated for clinically significant respiratory or circulatory depression. Patients require close monitoring for the potential recurrence of symptoms even after initial treatment.

Therapeutic Uses of Sufenta

What Sufenta Treats: Main Uses and Benefits

Sufentanil is commonly used in clinical settings to offer support that helps ease the overall burden of symptoms related to severe acute pain, such as the intense discomfort arising from major surgery. Its application is relevant across therapeutic areas involving heightened responses and is used for managing symptoms that become more disruptive during flare-ups and contributes to easing the overall symptom load for patients during high-stress procedures. Sufentanil is indicated as an analgesic adjunct in general anesthesia and for epidural administration to help manage pain during labor and delivery.

The medication plays a role in managing general anesthesia, where its use helps address symptoms related to heightened physiological activity (e.g., changes in heart rate and blood pressure) associated with surgical trauma. This application may assist with maintaining functional stability and helps managing the patient’s state of unconsciousness throughout complex operations.

“It provides supportive symptomatic relief in situations where additional management of discomfort is required for specialized or vulnerable patient groups.”

Sufentanil is applied in addressing major surgical procedures, specialized pain management for laboring patients, and the perioperative analgesia needs of pediatric and adult patients.

Quick Fact: Relief for Severe, Acute Pain

Sufentanil is reserved for conditions presenting with symptoms associated with acute or episodic changes and is used to offer symptomatic relief in highly controlled healthcare settings.

Eligibility and Restrictions for Use

Sufentanil eligibility is strictly defined by regulatory authorities and is generally limited to medically supervised settings. Certain populations are prohibited from use, while others require close monitoring due to pre-existing conditions.

Populations for Whom Use is Contraindicated

Absolute contraindications include a known hypersensitivity to sufentanil or other opioids, significant respiratory depression, acute or severe bronchial asthma (in unmonitored settings), and gastrointestinal obstruction (specific to sublingual tablets). Intravenous use for pain relief during vaginal delivery is also prohibited.

Restricted or Conditional Use

Eligibility is limited for specific groups:

Age: Use is generally not established or not recommended for children under two years. Older adults require caution due to potential for increased sensitivity.
Organ Function: Patients with severe hepatic or severe renal impairment should use with caution due to the risk of drug or metabolite accumulation.
Reproductive Status: The medicine is not recommended during pregnancy (due to risk of fetal harm) and lactation (as it is excreted in breast milk).

Other Restrictions

The sublingual tablet formulation is contraindicated in opioid-naïve adults and is not approved for home use or in children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Sufentanil details interaction patterns based on the drug's metabolic pathway and its pharmacodynamic effects. These interactions define specific restrictions and requirements for co-administration.

Metabolic (Pharmacokinetic) Interactions

Sufentanil is primarily cleared through the CYP3A4 enzyme system. Co-administration with CYP3A4 Inhibitors is documented to increase the Sufentanil plasma concentration and prolong its elimination half-life, a pharmacokinetic outcome that increases the risk of serious adverse reactions. Conversely, CYP3A4 Inducers may reduce Sufentanil exposure. This effect also suggests a potential interaction with certain substances, such as grapefruit or grapefruit juice, due to their inhibitory effect on CYP3A4.

Pharmacodynamic Interactions and Restrictions

Combining Sufentanil with CNS Depressants (including Benzodiazepines and alcohol) is documented to result in profound sedation, respiratory depression, coma, and death due to additive effects. Co-administration with Serotonergic Drugs (e.g., SSRIs) carries the risk of developing potentially life-threatening Serotonin Syndrome. Regulatory documentation advises mandatory avoidance of co-administration with Mixed Agonist/Antagonist Opioid Analgesics (e.g., nalbuphine), as this may reduce analgesic effect or precipitate opioid withdrawal symptoms. The risk of respiratory depression when interacting with CNS depressants is specifically noted as heightened in Elderly, Cachectic, or Debilitated Patients.

Mechanism of Action

Targeting Mu-Opioid Receptors and Signal Inhibition

Sufenta acts as a full agonist by directly binding to and activating mu-opioid receptors (mu-OR) found on nerve cells in the central nervous system. This molecular interaction initiates a cascade involving G-proteins that inhibits neurotransmitter release, effectively dampening the transmission of signals between neurons and leading to a reduction in overall neural activity.

Modulating Autonomic Regulatory Centers

The drug's activity extends to regulatory areas in the brainstem, altering the function of mu-ORs in centers that control involuntary processes. This targeted action affects systems where the drug is required to modulate autonomic activity, resulting in a direct physiological consequence: diminished response of the respiratory center to carbon dioxide, resulting in reduced ventilatory rate and tidal volume.

Altering Smooth Muscle Function

Sufenta also influences mu-ORs located on the involuntary smooth muscle of the gastrointestinal and biliary tracts. By engaging these peripheral mechanisms, the drug causes an increase in muscle tone. This effect slows down the natural, wavelike movements (peristalsis) of these internal organs, contributing to the drug's overall profile via diminished gastrointestinal motility due to increased smooth muscle tone.

Dosage and Administration Information

How to Use Sufenta

Sufenta (sufentanil) is administered exclusively in certified medically supervised healthcare settings by personnel trained in the use of potent opioids. The medicine is available in two official forms: a Solution for Injection for parenteral administration and a 30 mcg Sublingual Tablet housed in a single-dose applicator (SDA).

Administration and Dosing Regimens

The most common routes of administration are intravenous (IV) injection or continuous infusion, and epidural injection. Dosage is highly individualized based on the patient’s physical status, age, and the duration of the surgical procedure. For IV use as an analgesic adjunct, initial doses typically range from 1 to 8 mcg/kg, with subsequent maintenance increments of 10 to 50 mcg administered as needed.

Sublingual Use and Procedural Constraints

When the sublingual tablet is used for acute pain, it is administered as a 30 mcg single dose. The tablet must be placed under the tongue by a healthcare provider and not be chewed or swallowed. The patient must avoid eating, drinking, or excessive talking for 10 minutes after placement. Doses must be separated by a minimum interval of one hour. Treatment with the sublingual form is strictly time-bound, limited to a maximum of 12 tablets (360 mcg) in a 24-hour period, and is not authorized for use beyond 72 hours. Dose selection for groups such as older adults requires cautious consideration as part of the individualized dosing principle.

Recent Clinical Evidence

Sufenta: Recent Clinical Evidence

Recent clinical evidence continues to affirm the role of sufentanil (Sufenta) as a potent opioid analgesic in various surgical and pain management settings, with a focus on optimizing dosage and comparing its profile to other potent opioids.

Perioperative and Anesthesia Use

Clinical studies frequently investigate sufentanil as an intravenous (IV) adjunct to general anesthesia, particularly in major surgical procedures like cardiovascular or neurosurgery, due to its ability to maintain hemodynamic stability and provide rapid analgesia. When used as a primary anesthetic with 100% oxygen, very high doses of sufentanil can produce deep anesthesia and attenuate the body’s sympathetic response to surgical stress.

Postoperative Pain Management

Sufentanil is increasingly studied in patient-controlled analgesia (IV-PCA) for acute postoperative pain. Research indicates that compared to morphine, sufentanil may offer a higher therapeutic index and potentially a lower frequency of respiratory suppression. Evidence also supports the efficacy of a sublingual sufentanil tablet formulation (not IV Sufenta) for moderate-to-severe acute pain, offering a non-invasive administration route in settings like ambulatory surgery or the emergency department.

Comparative Analgesia

When comparing sufentanil to other synthetic opioids in the perioperative setting, specific benefits are noted:

Comparison Opioid	Clinical Finding	Context
Remifentanil	Lower postoperative pain scores; decreased need for rescue analgesia.	Robotic gynecological surgery.
Fentanyl	Similar duration of analgesia, but sufentanil may offer more stable hemodynamics and reduced postoperative agitation in pediatric patients.	Spinal anesthesia and pediatric surgery.

In spinal anesthesia for labor and delivery or cesarean sections, low-dose sufentanil is a common additive to local anesthetics, demonstrating improved quality and duration of analgesia, though side effects like pruritus (itching) and risk of hypotension are monitored.

Frequently Asked Questions (FAQ)

Common questions about Sufenta (FAQ)

Q: How quickly does Sufenta start working?

A: Official information indicates that Sufenta (sufentanil) has a rapid onset of action. When given intravenously, analgesia is typically within 1 to 3 minutes. For the sublingual tablet, pain relief is typically observed around 30 minutes after administration, according to product information.

Q: How long does the effect of Sufenta last?

A: The duration of action is described as being dependent on the specific dose and route of administration. The elimination half-life for the intravenous form in adults is approximately 164 minutes. For the sublingual tablet, the average terminal half-life after a single administration is in the range of 6 to 10 hours.

Q: What does 'Schedule II controlled substance' mean for Sufenta?

A: Sufenta is classified as a Schedule II controlled substance by regulatory authorities. This classification means the drug has a currently accepted medical use but also carries a high potential for abuse and dependence, which can lead to severe psychological or physical dependence.

Q: Does Sufenta show up on drug tests?

A: Sufentanil and the products created when the body processes it (metabolites) are detectable in the body using laboratory tests. Whether the drug is specifically identified depends on the particular panel of drugs included in the test being performed.

Q: What is the risk of dependence or addiction with Sufenta?

A: According to the official Boxed Warning, Sufentanil exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which are serious and can potentially lead to overdose and death. It is classified as a Schedule II opioid due to this high potential for abuse.

Q: Do you get withdrawal symptoms after using Sufenta?

A: As with any opioid, physical dependence can develop with the use of Sufentanil. If the drug is stopped suddenly after dependence has formed, withdrawal symptoms similar to those of other opioids may occur.

Q: Is there a maximum amount of time someone can be on Sufenta?

A: For the sublingual tablet formulation of Sufentanil, regulatory documents state that treatment is strictly limited to a maximum duration of 72 hours (3 days). The use of the intravenous injection or infusion is managed within the controlled medical setting without a fixed time limitation stated in the label, unlike the sublingual form.

Q: Why does the official information for Sufenta mention the potential for rigidity (muscle stiffness)?

A: Muscular rigidity, or muscle stiffness, is a known adverse reaction of Sufentanil and other potent opioids. Official information notes that the incidence and severity of this effect are related to the dose and the speed of intravenous administration. Like other potent opioids, the effect is believed to be mediated by the activation of mu-opioid receptors in the central nervous system.

Q: What is the 'Black Box Warning' for Sufenta about?

A: The FDA Boxed Warning (often called the Black Box Warning) highlights the most serious risks associated with Sufentanil. These critical safety concerns include Addiction, Abuse, and Misuse, the risk of Life-Threatening Respiratory Depression, and potential dangers from combining it with CYP3A4 inhibitors or CNS depressants (like benzodiazepines).

Q: Is Sufenta used to help patients breathe while on a ventilator?

A: Research indicates that Sufentanil is utilized in controlled settings, such as the Intensive Care Unit (ICU). It is one of the opioid medicines commonly used to provide pain relief and sedation for patients who are mechanically ventilated.

Q: Can Sufenta affect my mood or mental state?

A: Yes, Sufentanil acts on the central nervous system, and regulatory documents list sedation and dizziness as common side effects. Like other opioids, it has the potential to alter an individual's mood and perception.

Q: What kind of monitoring is done when a patient receives Sufenta?

A: Official safety constraints require patients to be monitored routinely for vital signs, including respiratory rate, when Sufentanil is administered. Close observation is critical for life-threatening respiratory depression and signs of addiction, abuse, or misuse. Postoperative monitoring and assisted respiration facilities must be readily available.

Q: Are there alternatives to Sufenta that are used for the same purpose?

A: Yes, other opioid analgesics are used for similar purposes in surgical and acute pain management. Official documentation indicates that Sufentanil is often compared in clinical studies to other potent opioids like Fentanyl and Remifentanil.

Q: Does Sufenta affect kidney function?

A: While Sufentanil is primarily broken down in the liver, official guidance states that patients with severe renal (kidney) impairment should receive the drug with caution. This is due to the potential risk of the drug or its inactive components accumulating in the body when kidney function is severely reduced.

Q: Do certain antibiotics interact with Sufenta?

A: Yes, Sufentanil's metabolism can be affected by certain drugs, including some antibiotics. Co-administration with drugs that inhibit the CYP3A4 enzyme (which breaks down Sufentanil) can increase the concentration of Sufentanil in the bloodstream, raising the risk of severe respiratory depression.

How should Sufenta be stored and disposed of?

Storage and Disposal of Sufentanil Citrate Injection

Sufentanil Citrate Injection is a Schedule II controlled substance requiring strict storage and disposal protocols.

Official Storage Requirements

Condition	Requirement
Temperature	Store at 20°C to 25°C (68°F to 77°F) (Controlled Room Temperature).
Light Protection	Product must be protected from light and retained in its original carton until use.

Child-Safety and Disposal Rules

Storage must follow proper control practices for a C-II drug, ensuring the product is kept out of the sight and reach of children to prevent accidental exposure. Disposal of any unused product is required as a strategy to reduce misuse. Unused opioid controlled substances must be disposed of following strict regulatory procedures, which often involves special collection programs or destruction protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.